A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127
Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
This is a phase 1 randomized double blind, first in human (FIH) study with the novel oral
Alzheimer drug candidate REM0046127, which consists of two main parts, a single ascending
dose (SAD) study with 7 cohorts followed by a multiple ascending dose (MAD) study with 2
cohorts.